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INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous 
hematopoietic malignant disorder resulting from genetic 
alterations that lead to deregulation of proliferation, 
differentiation and cell death in hematopoietic progenitors 
[1]. Although complete remission is often achieved 
after high-intensity chemotherapy in younger patients 
with AML, 5-year overall survival rate is about 40%, 
since most patients become resistant to chemotherapy 
and frequently relapse. For these patients with relapsed/
refractory disease therapeutic options are limited [1– 3]. 
Accumulating evidence indicates that incomplete 
eradication of aberrant self-renewal and drug-refractory 
leukemia stem cells (LSC) in bone marrow (BM) niche 
sites is responsible for disease relapse [4]. Importantly, 
TP53 alterations, that occur in around 8% of all AML 
patients and in 70% of patients with AML and complex 
karyotype, are associated to very bad prognosis [5, 6] and 
have a relevant role in the origin and evolution of therapy-
related AML [7]. Therefore, new targets and innovative, 
more potent drugs are urgently needed to improve both 
clinical outcomes and long-term quality of life, especially 
for poor-risk patients and those not eligible for intensive 
treatment or BM transplantation.
Most chemotherapeutic drugs induce apoptosis of 
cancer cells. The execution of apoptosis depends on the 
balance between pro- and anti-apoptotic BCL-2 family 
members [8]. These proteins control the mitochondrial 
outer membrane permeabilization (MOMP) and the 
release of mitochondrial intermembrane proteins such 
as cytochrome c [9]. In AML, it has been proposed that 
mitochondrial apoptotic priming of myeloblasts provided 
by BH3-only profiling predicts chemotherapeutic 
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ABSTRACT
Fluorizoline is a new synthetic molecule that induces apoptosis by selectively 
targeting prohibitins (PHBs). In this study, the pro-apoptotic effect of fluorizoline was 
assessed in two cell lines and 21 primary samples from patients with debut of acute 
myeloid leukemia (AML). Fluorizoline induced apoptosis in AML cells at concentrations 
in the low micromolar range. All primary samples were sensitive to fluorizoline 
irrespectively of patients’ clinical or genetic features. In addition, fluorizoline inhibited 
the clonogenic capacity and induced differentiation of AML cells. Fluorizoline increased 
the mRNA and protein levels of the pro-apoptotic BCL-2 family member NOXA both in 
cell lines and primary samples analyzed. These results suggest that targeting PHBs 
could be a new therapeutic strategy for AML.
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success [10]. Furthermore, recent studies show the 
importance of mitochondria functionality in maintaining 
AML cells, thus emerging as potential drug target [11].
Our group has described novel pro-apoptotic small 
molecules with fluorinated thiazole scaffolds [12]. The 
diaryl trifluorothiazoline compound 1a, hereafter referred 
to as fluorizoline (Figure 1A), was selected as the best 
apoptosis inductor in a wide range of cancer cell lines from 
different tissue origin, including hematopoietic cell lines, 
and with different p53 status, proving that fluorizoline 
exerts its anti-tumor action in a p53-independent manner 
[12]. Fluorizoline selectively binds to prohibitin (PHB) 
[12] and, strikingly, this protein is necessary for apoptosis 
induction by this compound [13]. Fluorizoline treatment 
induces mitochondrial-mediated apoptosis by controlling 
the expression of the BCL-2 family proteins. In this regard, 
induction of the pro-apoptotic BH3-only protein NOXA 
is required for fluorizoline-induced apoptosis and BIM is 
also involved depending on the cellular context [13].
Two homologous prohibitin proteins, PHB1 
and PHB2, have been described [14, 15]. Increasing 
evidences link PHBs to tumorigenesis even though the 
role of PHBs in tumor growth and/or tumor suppression 
is still controversial [16, 17]. In acute promyelocytic 
leukemia cells (APL), PHBs co-immunoprecipitate with 
α-dystrobrevin [18]. Interestingly, nuclear PHB2 is an 
AKT substrate during all-trans-retinoic acid (ATRA)-
induced differentiation and phosphorylation of PHB2 is 
necessary for cell survival [19]. On the other hand, it has 
been reported that downregulation of PHB expression 
protects from spontaneous apoptosis in ATRA-resistant 
cells [20]. The objective of this work was to investigate 
the effect of fluorizoline in AML cells and further dissect 
its mechanism of action.
RESULTS
Fluorizoline treatment induces apoptosis in AML 
cell lines
First, we tested the effect of fluorizoline (Figure 1A) 
in the AML cell lines HL-60 and U-937. Both cell lines 
express PHB1 and 2 (Figure 1B) and were sensitive 
to fluorizoline (Figure 1C–1F). When determining 
cell viability by the MTT assay, a dose-dependent 
decrease of cell viability was observed in both cell lines 
(Figure 1C– 1D), with IC50 (half-maximal inhibitory 
concentration) values of 8 and 6 µM at 24 and 48 hours, 
respectively, in HL-60 cells, and 7 and 5 µM at 24 and 
48 hours, respectively, in U-937 cells. Next, whether 
fluorizoline induced apoptosis in U-937 cells was analyzed 
by flow cytometry. Fluorizoline treatment induced the 
annexin V+/propidium iodide− (PI−) and the annexin V+/PI+ 
cell populations (Supplementary Figure S1). Importantly, 
the pan-caspase inhibitor Q-VD-OPh was able to prevent 
the pro-apoptotic activity of fluorizoline and the annexin 
V−/PI+ population represented less than 6% of cells. 
Thus, we examined fluorizoline-induced apoptosis using 
annexin V staining by flow cytometry. Apoptotic cells 
were detected in the HL-60 cell line after 48 hours of 
fluorizoline treatment, reaching LD50 (half-maximal lethal 
dose) at 40 µM (Figure 1E). In U-937 cells, fluorizoline 
induced apoptosis in a dose-dependent manner (Figure 1F) 
with a mean LD50 value above 40 µM at 24 hours and 
14 µM at 48 hours. Finally, the structurally similar 
inactive analog compound 2a [12] as well as equivalent 
concentrations of the vehicle DMSO did not affect cell 
viability (Supplementary Figure S2). Taken together, these 
data demonstrate that fluorizoline effectively induces 
apoptosis in AML cell lines.
Fluorizoline treatment induces apoptosis in AML 
primary blasts
Next, the cytotoxicity of fluorizoline was evaluated 
in samples obtained from patients with AML who had not 
previously received any treatment (see Table 1 for details 
of patients and samples). PHBs protein levels were similar 
in all primary samples (data not shown and Figure 6). 
Cells from 21 different patients were exposed ex vivo to a 
range of fluorizoline concentrations (from 1.25 to 20 µM). 
The mutational status of FLT3 and NPM1, the two most 
frequent mutations found in AML [3, 5], was analyzed in 
most patient samples. The association of the antileukemic 
effect of fluorizoline in AML primary samples according 
to cytogenetic risk categories or according to the clinical 
response to standard chemotherapy was analyzed 
by Fisher’s exact test and no statistically significant 
associations were found (p > 0.5 in all categories) 
(Table 1). In leukemic primary BM or PB mononuclear 
cells (BMMNC and PBMNC, respectively) incubation 
with fluorizoline strongly reduced cell viability in a dose-
dependent manner (Figure 2A). Most AML samples were 
sensitive to fluorizoline at 24 hours, and cell viability 
decreased from 75.8% ± 2.9% to 35.5% ± 4.0% after 
incubation with 10 µM fluorizoline (n = 20) (Figure 2B), 
with LD50 values ranging from 1.5 to 20 µM (median 
8.0  ± 1.7 µM) for sensitive patient samples (n = 15) 
(Table 1 and Supplementary Figure S3). Longer exposition 
to fluorizoline for 48 hours slightly reduced the mean LD50 
value to 5.3 ± 0.8 µM (n = 21) (Table 1), being all samples 
sensitive to the compound. It is noteworthy that no 
difference was observed between samples obtained at the 
debut and after disease progression, even those samples 
derived from the same patient, with median LD50 values 
of 10.3 ± 4.0 µM and 5.4 ± 1.6 µM at 24 and 48 hours, 
respectively (n = 6 samples at relapse; Supplementary 
Figure S4). Incubation with 10 µM fluorizoline induced 
a time-dependent decrease of cell viability being evident 
at 8 hours in a subset of patient samples (Figure 2C). 
Blasts from PB and BM derived from the same patient 
were similarly sensitive to fluorizoline (Figure 2D). 
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response● 24 h† 48 h†
1 65/M AML with myelodysplasia-related changes M0
47,XY,t(2;11)(p21;q23),-9,-
14,+22,+mar1,+mar2[16]/46,XY[4] wt/wt H CR > 5 2.5
2 80/F AML with myelodysplasia-related changes* M0
46,XX,t(10;20)(q22;q11.2)
[19]/46,XX[1] nd/nd ND Ut 6 4






wt/wt H Ut 20 5
4 64/M AML without maturation M1 47,XY,+8[18]/46,XY[2] wt/wt I R 15 5
5 86/F AML with myelodysplasia-related changes** ND ND nd ND Ut 3 3
6 34/F AML with t(9;11)(p22;q23); MLLT3-MLL M5a 46,XX,t(9;11)(p22;q23)[20] wt/wt H CR 9 3
7 40/M AML with t(3;3)(q21;q26.2); RPN1-EVI1 M7
45,X,-Y,t(3;3)(q21;q26)
[18]/46,XY[2] wt/wt H R > 20 12
8 79/M Acute undifferentiated leukemia with ambigous lineage M0 46,XY[20] nd ND U 5 4.5
9 57/M AML with mutated NPM1 M5b 46,XY[30] wt/mut L CR > 20 4
10 66/F
AML with myelodysplasia-
related changes and mutated 
NPM1
M2 46,XX[30] wt/mut L CR 13 8
11 57/M AML with myelodysplasia-related changes* M1 47,XY,+8[20] itd/wt H CR 5 3
12 55/M AML with mutated NPM1 RAEB-T 46,XY[20] wt/mut L CR 2.5 2
13 55/F AML with inv(16)(p13.1q22); CBFB-MYH11*** M4Eo 46,XX[20] wt/ wt L CR 11 6
14 55/M AML with mutated NPM1 M5a 47,XY,+8[13]/46,XY[7] itd/mut H ND 4 4
15 62/M AML with myelodysplasia-related changes M2
46,XY,del(5)(q13q33)
[10]/46,XY[10] wt/wt H R 20 7.5
16 65/F AML with mutated NPM1 M1 46,XX[18] itd/ mut L U > 20 8
17 24/M AML with myelodysplasia-related changes M1
47,XY,+8[11]/52,
sl,+3,+6,+10,+13,+19[9] itd/ wt H R > 20 5
18 74/M AML with myelodysplasia-related changes RAEB-T 46,XY,-7,+9[12]/46,XY[5] wt/wt H U 2.5 2.5
19 60/M AML with maturation M2 46,XY[8] wt/wt I CR 3 2
20 40/M AML without maturation M1 46,XY[30] wt/wt I CR > 20 17
21 56/F
Acute promyelocytic leukemia 
with t(15;17)(q22;q12); PML-
RARA
M3 46,XX,t(15;17)(q24;q21)[20] nd/nd L CR 1,5 3
Patient samples were considered sensitive when a LD50 < 20 µM fluorizoline was reached. †LD50 values for sensitive patient samples 
at 24 and 48 hours are shown. ∆Cytogenetic and molecular risk categories defined by the Medical Research Council and the European 
LeukemiaNet prognostic classification. ●Idarubicin at dose of 12 mg/m2 daily for 3 days and cytarabine at a dose of 200 mg/m2 daily 
for 7 days as a continuous infusion were considered the standard induction therapy. The consolidation treatment consisted of high 
dose of cytarabine or allogeneic hematopoietic stem cell transplantation depending on the AML risk classification according to the 
CETLAM protocol. *Morphologic criteria. **Multilineage dysplasia and previous history of myelodysplastic syndrome. ***Cryptic 
translocation. CBFB-MYH11 was demonstrated by molecular genetic studies. FAB, French–American–British classification systems; 
M, male; F, female; RAEB-T, refractory anemia with excess of blasts in transformation; WT, wild type; D835, mutation of the Asp 
codon 835 within the activation loop of the FLT3 gene; Mut, mutated; ND, not determined; H, high; I, intermediated; L, low; CR, 
complete remission; U, untreated; R, refractory; CETLAM, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas 
y Mielodisplásicas.
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These results therefore indicate that fluorizoline induces 
apoptosis in primary AML cells.
To examine the effects on the leukemic cells more 
specifically, apoptosis induction was assayed in the CD34+ 
and CD34− populations of six AML specimens. The 
reduction in cell viability in the presence of fluorizoline 
was higher within the CD34+ population (LD50 value 
of 4.5 ± 2.3 µM at 48 hours) compared to the CD34− 
population, which was more resistant (LD50 value higher 
than 20 µM at 48 hours) (Figure 3A). This suggests that 
the fluorizoline cytotoxic effect is preferentially displayed 
on the AML compartment.
Finally, to evaluate the cytotoxicity of fluorizoline 
in non-malignant cells, the effect of fluorizoline on 
normal BMMNC and normal hematopoietic stem cells 
(PBSC) was assessed (see Table 2 for details of healthy 
volunteers and samples). Incubation with increasing doses 
of fluorizoline slightly reduced the percentage of viable 
normal cells (68.6% ± 7.0% of viable cells after 24 hours 
of treatment with 20 µM fluorizoline) (Figure 3B) 
with a median LD50 value above 20 µM both at 24 and 
48 hours (Table 2), suggesting a higher resistance of 
normal hematopoietic and stromal cells to fluorizoline, as 
compared to leukemic cells.
Figure 1: Cytotoxicity of fluorizoline in AML cell lines. (A) Chemical structure of fluorizoline. (B) Whole cell lysates from HL-60 
and U-937 cell lines were obtained and total protein levels of PHB1 and PHB2 were analyzed by western blot. Tubulin was used for loading 
normalization. (C and E) HL-60 cells and (D and F) U-937 cells were incubated for 24 and 48 h with increasing doses of fluorizoline 
ranging from 2.5 to 40 µM. (C and D) MTT metabolization was measured by absorbance and is expressed as the mean  ±  SEM (n ≥ 3) of 
the percentage of the value of untreated cells. (E and F) Viability was measured by analysis of phosphatidylserine exposure and is expressed 
as the mean  ±  SEM (n ≥ 3) of the percentage of non-apoptotic (annexin V negative) cells. Two-tailed paired Student’s t test significant 
p values are indicated: *p < 0.05; **p < 0.01; ***p < 0.001 treated versus untreated cells.
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Table 2: Healthy donors’ characteristics
Donor No. Disease* Sample origin LD50 (µM)24 h*
LD50 (µM)
48 h*
1 DLBCL BM > 20 > 20
2 HD/G-CSF Apheresis > 20 > 20
3 HD BM > 20 > 20
4 Adenopathy BM > 20 > 20
5 FL BM > 20 > 20
6 Trombocytosis BM > 20 > 20
7 FL BM > 20 13
8 DLBCL BM > 20 > 20
9 FL BM 16 8
Donors were considered sensitive when a LD50 < 20 µM fluorizoline was reached. * LD50 values for sensitive donors are 
shown. DLBCL, diffuse large B-cell lymphoma; HD, healthy donor; FL, follicular lymphoma.
Figure 2: Cytotoxicity of fluorizoline in primary AML cells ex vivo. (A) Dose response of fluorizoline on primary AML cells. 
BMMNC or PBMNC from 21 newly diagnosed AML patients were incubated for 24 and 48 h with increasing doses of fluorizoline 
ranging from 1.25 to 20 µM. (B) Blasts from 21 AML patients were incubated for 24 h without or with 10 µM fluorizoline. White filled 
shapes represent 5 patient samples with LD50 values >20 µM. (C) Time course of fluorizoline-induced apoptosis in AML cells. Cells from 
6 patients (#13, 14, 16, 18, 20 and 21) were incubated for different times ranging from 2 to 48 h with 10 µM fluorizoline (F) (except patient 
#21, whose sample was treated with 2.5 µM fluorizoline) or with equivalent concentrations of the vehicle DMSO (D). (D) BMMNC or 
PBMNC from 3 patients (#6, 10 and 11) incubated for 24 h with increasing doses of fluorizoline ranging from 1.25 to 10 µM. (A, B, C 
and D) Viability was measured by analysis of phosphatidylserine exposure and is expressed as the percentage of non-apoptotic (annexin V 
negative) cells (in B and D) or as the percentage of the viability (annexin V negative) of untreated cells (in A) or as the percentage of the 
viability of cells at 0 h (in C). Data are shown as the mean  ±  SEM (in A and C). Two-tailed paired Student’s t test significant p values are 
indicated: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 treated versus untreated (in A) or DMSO-treated cells at each time point (in C).
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Fluorizoline inhibits the clonogenic capacity and 
induces differentiation of AML cells
We performed methylcellulose colony-forming unit 
(CFU) assays to determine whether fluorizoline would 
functionally affect the ability of cells to form leukemic 
cell colonies. CFU assays showed that fluorizoline 
significantly reduces clonogenic capacity of U-937 cells 
at 5 μM and completely abolishes it at 10 μM (mean 
CFU respect to untreated cells, 49.9 ± 5 % for 5 μM and 
1.9 ± 1% for 10 μM; n = 4). Next, we assessed the effects 
of fluorizoline on human primary leukemia blasts isolated 
from 5 AML patients. Fluorizoline treatment strongly 
reduced the ability of primary AML cells to form colonies 
(mean CFU respect to untreated cells, 39.9 ± 5 % for 
2.5 μM and 5.3 ± 1.5 % for 10 μM; n = 5).
We next assessed the effect of fluorizoline on 
myeloid maturation of U-937 cells as well as AML 
patient-derived cells. The expression of the granulocyte/
monocyte/macrophage differentiation marker CD11b 
[19, 21] was upregulated at 24 hours of incubation with 
fluorizoline, being especially evident after 48 hours of 
treatment (not shown). The induction of CD11b surface 
marker expression by fluorizoline was dose-dependent 
(12.1- and 1.5-fold induction in 40 µM fluorizoline-treated 
U-937 cells (Figure 4A) and 20 µM fluorizoline-treated 
de novo AML primary samples (Figure 4B), respectively, 
compared to DMSO-treated cells at 48 hours) and 
occurred in parallel to cell viability decrease (Figure 4A 
and 4B). Conversely, the vehicle DMSO did not induce 
the expression of CD11b (Figure 4A and Supplementary 
Figure S5). These findings suggest that fluorizoline acts as 
a differentiation-inducing drug of AML cells.
Fluorizoline induces upregulation of NOXA in 
AML cell lines
To gain insight into the molecular mechanism of 
fluorizoline-induced cytotoxicity in AML, changes in 
overall apoptosis-related gene expression profile were 
Figure 3: Ex vivo cytotoxicity of fluorizoline in AML cells and in healthy bone marrow and blood myeloid cells. (A) Dose 
response of the cytotoxic effect of fluorizoline on CD34+ and CD34- populations. BMMNC or PBMNC from 6 AML patients (#1, 2, 18, 19, 
20 and 21) were incubated for 48 h with increasing doses of fluorizoline ranging from 1.25 to 20 µM. Viability was measured on CD34− 
and CD34+ populations. (B) Comparative dose response of the cytotoxic effect of fluorizoline on normal hematologic cells and AML cells. 
BMMNC from 8 healthy BM or PBSC from one G-CSF-mobilized healthy donor (HD), and BMMNC or PBMNC from 21 newly diagnosed 
AML patients (AML) were incubated for 24 h with increasing doses of fluorizoline ranging from 1.25 to 20 µM. In normal cells viability was 
measured on total buffy coat population. (A and B) Viability was measured by analysis of phosphatidylserine exposure and is expressed as 
the percentage of the viability (annexin V negative) of untreated cells. Data are shown as the mean  ±  SEM. Two-tailed unpaired Student’s 
t test significant p values are indicated: *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 CD34+ versus CD34− cells, or normal versus malignant cells.
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analyzed by reverse transcriptase multiplex ligation-
dependent probe amplification (RT-MLPA) in the U-937 
cell line. Fluorizoline mostly upregulated the BH3-only 
NOXA at the mRNA level from the early 4 hours of 
incubation (3.5-, 6.6- and 3.1-fold induction at 4, 8 and 
24 hours of incubation, respectively) (Figure 5A and 
Supplementary Figure S6A). Also, fluorizoline induced 
the expression of NOXA protein from the early 4 hours 
and the degradation of the anti-apoptotic MCL-1 after 
24  hours of incubation (Figure 5B). Both NOXA mRNA 
and protein highest expression levels were observed after 
8 hours of incubation, and the expression was higher than 
in the untreated conditions until 24 hours (Supplementary 
Figure S7). Neither BIM nor PHB1/2 protein levels were 
modified upon fluorizoline treatment in U-937 cells. It 
should be noted that BIMEL was the main expressed BIM 
isoform in U-937 cells [22, 23] (Figure 5B). Regarding 
the apoptotic features involved in the cytotoxic effect of 
fluorizoline, the cleaved fragment of caspase 3 as well as 
the proteolysis of the caspase substrate PARP were found at 
8 hours of incubation with fluorizoline, and both events were 
clearly detected after 24 hours of treatment (Figure 5B). 
Conversely, the inactive compound 2a did not induce 
caspase 3 and PARP cleavage nor NOXA upregulation 
(Supplementary Figure S6A and S6B). Interestingly, 
fluorizoline-induced NOXA upregulation was still detected 
whereas MCL-1 degradation was reverted when caspase 
activity was blocked with the pan-caspase inhibitor Q-VD-
OPh (Figure 5C and Supplementary Figure S7B), thus 
demonstrating that only the induction of NOXA precedes 
caspase activation. These results indicate that fluorizoline 
causes an increase of NOXA mRNA and protein levels prior 
to caspase activation and these modulations could explain 
the apoptotic outcome observed in the AML cell line U-937.
NOXA is upregulated by fluorizoline in primary 
AML cells
To validate the mechanism of apoptosis induction 
upon fluorizoline treatment in primary AML samples, 
Figure 4: Effect of fluorizoline on the expression of the differentiation marker CD11b in AML cells. (A) U-937 cells were 
incubated for 48 h with increasing doses of fluorizoline (F) ranging from 2.5 to 40 µM or equivalent concentrations of the vehicle DMSO 
(D), and CD11b expression and viability were analyzed. (B) Blasts from AML patients (#6, 17, 18 and 22) were incubated for 48 h with 
increasing doses of fluorizoline (F) ranging from 1.25 to 20 µM, and CD11b expression and viability were analyzed. (A and B) CD11b 
expression was measured by flow cytometry and is expressed as the percentage of CD11b+ population. Viability was measured by analysis 
of phosphatidylserine exposure and is expressed as (A) the percentage of non-apoptotic (annexin V negative) cells and (B) the percentage 
of the viability (annexin V negative) of untreated cells. Data are shown as the mean  ±  SEM of (A) 3 independent experiments and (B) at 
least 2 AML patients (n = 2 at 24 h; n = 4 at 48 h). Patient #22 sample does not appear in Table 1 as viability data are not available at 24 h. 
Two-tailed paired Student’s t test significant p values are indicated: *p < 0.05; **p < 0.01; ***p < 0.001 treated versus untreated cells.
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the changes in apoptosis-related gene expression were 
analyzed. Treatment of patient samples with fluorizoline 
increased the expression of the pro-apoptotic BCL- 2 
family members BIM, NOXA and MOAP1 in a time-
dependent manner, along with a decrease in the mRNA 
levels of the anti-apoptotic members BCL-W, BCL-2 
and BFL-1, although these downregulations were not 
statistically significant (Figure 6A and Supplementary 
Figure S8). The induction timing of these genes was 
patient-dependent and it mostly occurred during the first 
8 hours of treatment, preceding the loss of cell viability 
in some cases (Supplementary Figure S9). At longer 
times, we also observed the induction of PUMA mRNA 
levels (Supplementary Figure S8). The expression 
of other apoptosis-related genes was also regulated 
upon fluorizoline treatment: p21 was upregulated and 
some members of the IAP family (HIAP2, SURVIVIN 
and NAIP) were downregulated (Supplementary 
Figure S8). Modulation of the mRNA levels of NOXA 
led to upregulation of the protein (Figure 6B and 6C). 
The increment of NOXA protein expression was time-
dependent and it was detected at the early 4 hours of 
incubation when cell viability was not affected yet 
(Figure 6B and Supplementary Figure S7). NOXA 
accumulation also preceded downregulation of anti-
apoptotic MCL-1. PUMA protein expression decreased 
Figure 5: Fluorizoline modulates the expression of BCL-2 family members in the U-937 AML cell line. (A) U-937 cells 
were untreated (U) or treated with 10 μM fluorizoline (F) for 8 h. BCL-2 family members mRNA levels were analyzed by RT-MLPA. Data 
show the mean  ±  SEM (n = 2) of the mRNA expression levels. (B) U-937 cells were untreated (U) or treated with equivalent concentrations 
of the vehicle DMSO (D) for 24 h and with 5 μM fluorizoline for 4, 8 and 24 h, as indicated. (C) U-937 cells were untreated (U) or pre-
incubated with 20 μM caspase inhibitor Q-VD-OPh (Q) for 30 min and then treated with 5 μM fluorizoline (F) for 24 h. Cells were also 
incubated with equivalent concentrations of the vehicle DMSO (D) for 24 h. (B and C) Protein levels from whole cell lysates were analyzed 
by western blot. Tubulin was used as a loading control. These are representative images of at least three independent experiments. Viability 
was measured by analysis of phosphatidylserine exposure and is expressed as the percentage of non-apoptotic (annexin V negative) cells.
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or remained stable, and BIM and PHBs protein levels 
were not modified upon fluorizoline treatment (Figure 6B 
and 6C). Similarly, expression levels of PHBs were not 
modified in normal hematopoietic cells (Supplementary 
Figure S10). Also, fluorizoline clearly induced caspase 3 
cleavage and PARP proteolysis after 8 hours of treatment 
(Figure 6B and 6C), thus confirming an apoptotic 
mechanism. Finally, as described for the U-937 AML 
cell line, increases in NOXA preceded caspase activation, 
as pre-incubation with the pan-caspase inhibitor Q-VD-
OPh did not block its upregulation (Figure 6D and 
Supplementary Figure S7). In contrast, caspase inhibition 
abolished the fluorizoline-mediated decrease in MCL-1, 
thereby demonstrating that only NOXA upregulation is 
a caspase-independent event in primary AML samples. 
Taken together, these results indicate that NOXA is 
Figure 6: Induction of NOXA mRNA and protein levels upon fluorizoline treatment in primary AML samples. (A, 
B and C) BMMNC or PBMNC from patients #13, 14, 16, 18, 20 and 21 were incubated for different times ranging from 2 to 24 h with 
10 µM fluorizoline (F or +) (except patient #21, whose sample was treated with 2.5 µM fluorizoline) or with equivalent concentrations of 
the vehicle DMSO (D or -). (A) After 8 h of treatment, RNA from cells was extracted and analyzed by RT-MLPA and the results for BCL-
2 family members are shown as the mean  ±  SEM (n = 6) of the mRNA expression levels. Two-tailed paired Student’s t test significant 
p values are indicated: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 treated versus untreated cells. (B) After the times stated at the figure, cells from 
patient #14 were collected. (C) After 8 h of treatment, cells from patients #13, 16, 18, 20 and 21 were collected. (D) Cells from patient 
#20 were pre-incubated with 20 μM caspase inhibitor Q-VD-OPh for 30 min and then treated with 10 μM fluorizoline for 24 h. (B, C 
and D) Cells were lysed and analyzed by western blot. Tubulin was used for loading normalization. Viability was measured by analysis 
of phosphatidylserine exposure and is expressed as the percentage of non-apoptotic (annexin V negative) cells. These are representative 
patient samples of at least three analyzed (n = 6 for B and C; n = 3 for D). 
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involved in the mechanism of fluorizoline-induced 
apoptosis in primary AML cells.
DISCUSSION
In the present study we describe that the prohibiting-
binding compound fluorizoline induces apoptosis in 
AML cells, including a series of primary samples. Our 
results suggest that PHB has a pro-survival role in AML 
that is inhibited by the selective binding of fluorizoline. 
Furthermore, we describe that flourizoline is able to impair 
the ability of primary AML cells to form colonies, which 
provides evidence that fluorizoline inhibits the growth of 
AML progenitors cells.
Treatment with ATRA plus arsenic trioxide (ATO), 
which degrades the PML/RARα fusion protein, results 
in the differentiation of APL cells and is the only highly 
effective molecular targeted strategy for AML [24]. 
Interestingly, we have observed that fluorizoline induces 
differentiation of primary AML cells even though these 
patients did not express the translocation t(15;17) and 
could not benefit from ATRA differentiating therapy. 
Thus, the mechanism by which fluorizoline induces 
differentiation of AML cells is independent of the 
expression of the PML/RARα fusion protein.
The mitochondrial or intrinsic pathway of apoptosis, 
controlled by the BCL-2 family proteins, is thought to be 
the main mechanism of AML cell killing by chemotherapy 
[26]. Increased levels of the anti-apoptotic family members 
BCL-2, BCL-XL and/or MCL-1 have been found to 
predict poor prognosis of AML patients to chemotherapy 
[27–30]. Expression of BCL-XL, BCL-2 and MCL-1 is 
heterogeneous and overlapping within AML subtypes, 
suggesting functional redundancy [31]. Molecular studies 
revealed that MCL-1 is overexpressed in AML and plays 
an even more important role than BCL-2 or BCL-XL in 
protecting AML cells from apoptosis [32, 33]. AML bulk 
and stem cells are dependent on the anti-apoptotic BCL-2 
members for survival, and their inhibition causes cell 
death in AML cells [34, 35].
Expression analysis revealed a consistent 
upregulation of NOXA both in cell lines and primary 
AML cells upon fluorizoline treatment. Fluorizoline 
induced increases in NOXA protein levels prior to caspase 
activation, which could explain the apoptotic outcome 
in AML cells. The expression of BIM protein was not 
modulated by fluorizoline in AML cells, similarly to 
other cells of hematological origin [13]. Fluorizoline also 
downregulated the expression of MCL-1 in AML cells, 
although this effect was dependent on caspase activation 
and would not be involved in the primary apoptotic 
mechanism of the drug. NOXA has been described as a 
particularly relevant pro-apoptotic BCL-2 family member 
in different cell types [36]. NOXA protein is induced 
in AML cells by HDAC inhibitors [37, 38], MDM2 
inhibition [39], Aurora B kinase inhibitors [40], inhibition 
of Nedd8 activating enzyme [41, 42], hyperforin [43] and 
dihydroartemisinin [44]. Our results emphasize the role of 
NOXA in the induction of apoptosis in AML cells.
Novel therapies that effectively achieve cancer 
cell killing with minimal toxicity to normal cells are 
urgently needed for AML. Our results indicate that 
fluorizoline induces apoptosis in AML cells through 
NOXA upregulation by preferentially affecting leukemic 
immature progenitor cells while sparing normal cells. 
This data suggest that targeting PHBs could be a new and 
interesting therapy for AML.
MATERIALS AND METHODS
Cell lines
Human AML cell lines HL-60 and U-937 (kindly 
provided by Dr. Pablo Engel, Universitat de Barcelona) 
were maintained in RPMI 1640 culture medium 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, 
and 100 µg/mL streptomycin (all supplied by Biological 
Industries, Kibbutz Beit HaEmek, Israel) at 37ºC in a 
humidified atmosphere containing 5% carbon dioxide.
Primary AML samples, healthy donors and cell 
isolation
PB samples and BM aspirates from 21 newly 
diagnosed and untreated patients with AML (Table 1) 
were obtained after informed consent in accordance 
with protocols approved by the Human Research Ethics 
Committees of the Hospital ICO-Duran i Reynals, 
L’Hospitalet de Llobregat, Barcelona, Spain. AML was 
diagnosed and classified according to standard clinical 
and laboratory criteria, according to the classification of 
the World Health Organization (WHO) [45]. Caryotype 
was determined by G-banding [46]. Internal tandem 
duplications (ITD) and mutations of the gene FLT3 
(fms related tyrosine kinase 3) were determined by 
polymerase chain reaction (PCR) [47,48]. Mutations of 
the gene NPM1 (nucleophosmin) were determined by 
PCR [49].
PBMNC and BMMNC were isolated by 
centrifugation on a Biocoll (Biochrom AG, Berlin, 
Germany) gradient and cryopreserved in liquid nitrogen 
in the presence of 10% dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich Inc, St Louis, MO, USA). MNC were 
cultured immediately after thawing or isolation at a 
concentration of 1 × 106 cells/mL in RPMI 1640 culture 
medium supplemented with 10% heat-inactivated FBS, 2 
mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL 
streptomycin (all from Biological Industries) at 37ºC in 
a humidified atmosphere containing 5% carbon dioxide.
Normal BMMNC was obtained from apheresis-
collected granulocyte colony-stimulating factor 
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(G-CSF)-mobilized progenitor-cell from PB of 3 healthy 
donors were used as a source of normal CD34+ cells.
Circulating B and T lymphocytes from healthy donors 
were purified by negative selection (RosetteSep™ Human 
B Cell Enrichment Cocktail and RosetteSep™ Human 
T Cell Enrichment Cocktail, StemCell Technologies, 
respectively) previously to Biocoll gradient centrifugation 
and then used as normal hematopoietic cells.
Reagents
Fluorizoline (a diaryl trifluorothiazoline; see 
molecular structure in Figure 1A) and compound 2a 
(a non-fluorinated diaryl thiazole synthetic precursor of 
fluorizoline; see molecular structure in Supplementary 
Figure 2A) were synthesized as previously described 
[12] and dissolved in DMSO at 20 or 100 mM. 
Allophycocyanin (APC)-Cy7-labeled antibody against 
human CD11b was purchased from BD Biosciences 
(Franklin Lakes, NJ, USA). APC-Alexa Fluor 750 anti-
human CD33 was purchased from Beckman Coulter 
(Marseille, France). APC-Cy7 anti-human CD34 was 
from Sony Biotechnology Inc. (Champaing, IL, USA). 
APC-conjugated annexin V was purchased from 
eBiosciences (San Diego, CA, USA). Q-VD-OPh was 
from R&D Systems (Minneapolis, MN, USA). MTT 
((3-4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide) was from Sigma-Aldrich. PI was purchased from 
eBiosciences (San Diego, CA, USA).
Analysis of cell viability by the MTT assay
HL-60 and U-937 cells (1.25 × 105 cells/well) 
were incubated in the absence or in the presence of the 
indicated factors, in a final volume of 250 µL. After 24 
or 48 hours, 25 µL MTT reagent (prepared at 5 mg/mL 
in phosphate-buffered saline (PBS)) was added to each 
well for an additional 3 hours. The blue MTT formazan 
precipitate was dissolved in 250 µL isopropanol:1 M HCl 
(24:1). Then, 100 µL of this cell lysate were plated in a 
96-well plate in triplicate and the absorbance values at 
570 nm were measured on a multiwell plate reader. The 
half-maximal inhibitory concentration (IC50) was defined 
as the concentration of drug required to reduce the MTT 
metabolization ability by 50%.
Analysis of cell purity and cell viability by flow 
cytometry
Cell viability was assessed by phosphatidylserine 
exposure and measured as the percentage of annexin 
V-negative cell population. After incubation of 1.25 × 105 
cells with the indicated factors and times, cells were then 
washed in annexin-binding buffer (ABB) and incubated 
in 100 µL ABB with 0.5 µL annexin V-APC for 10 min 
in the dark and then diluted with ABB to a final volume 
of 150 µL. Occasionally, 3.75 µL PI were added after 
annexin V staining and immediately before acquisition 
to measure the percentage of annexin V−/PI− live cells. 
In AML samples with infiltration lower than 80% blasts, 
double staining with anti-CD33 or anti-CD34, and annexin 
V was performed. In brief, cells were washed in ABB 
and incubated in 50 µL ABB containing 0.5 µL anti-
CD33 or anti-CD34 for 10 min in the dark and thereafter 
stained with annexin V, as previously mentioned. Cells 
were acquired using the FACSCantoTM II flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA) and data 
of bulk leukemic/normal and CD33+- or CD34+-gated 
leukemic/normal progenitor cells were analyzed using the 
FACSDivaTM software (Becton Dickinson). Half-maximal 
lethal dose (LD50) was defined as the concentration of 
drug required to reduce the cell viability by 50%. Patient 
samples were considered as “sensitive” to fluorizoline 
when cell viability was lower than 80% after incubation 
with 20 µM during 48 hours.
Colony-forming unit (CFU) assay
The analysis of the clonogenic capacity after 
exposition to the fluorizoline was performed using 
a methylcellulose-based medium with recombinant 
cytokines and erythropoietin (EPO) for human 
hematopoietic progenitor cells (MethoCultTM H4034 
Optimum, StemCell Technologies). U-937 cells and 
primary AML cells were pretreated for 24 hours with the 
indicated factors, as previously mentioned. Then, cells 
(1 × 103 U-937 cells or 50 × 103 primary AML cells) were 
diluted in 100 µL serum-free IMDM with 25 mM HEPES, 
homogeneously mixed with 1 mL MethoCultTM medium, 
seeded in duplicate cultures and maintained at 37°C with 
5% CO2 in air in a humidified atmosphere. Colonies (CFU) 
were screened based on morphology and cellularity at day 
10 (U-937 cells) or day 14 (primary AML cells) using an 
inverted microscope. A colony was defined as a cluster of 
> 40 cells.
Differentiation assay
Myeloid maturation induction was assessed 
by cell surface marker expression analysis [19, 21]. 
U-937 and primary AML cells were treated as indicated 
for cell viability assays. After 24 and 48 hours of 
incubation cells were collected and stained in 50 µL 
PBS buffer containing 2 mM EDTA and 0.5% bovine 
serum albumin (BSA) with 0.5 µL anti-human CD11b 
for 10 min in the dark and then diluted with buffer to 
a final volume of 150 µL. In parallel, cell viability was 
analyzed by annexin V staining in separated tubes. 
Surface expression of the antigen was analyzed by flow 
cytometry. In these experiments vehicle-treated cells 
were also included in order to discard DMSO-induced 
myeloid differentiation [19].
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Reverse transcriptase multiplex ligation-
dependent probe amplification (RT-MLPA)
RNA was isolated from cultured 3–5 × 106 cells by 
the RNeasy Micro kit (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s protocol. RNA was 
analyzed by RT-MLPA using SALSA MLPA KIT R011-C1 
Apoptosis mRNA from MRC-Holland (Amsterdam, 
The Netherlands) for the simultaneous detection of 40 
messenger RNA molecules, including apoptosis-related 
genes [13, 50]. In brief, RNA samples (200 ng total RNA) 
were first reverse transcribed using a gene-specific primer 
mix. The resulting cDNA was annealed overnight at 60ºC 
to the RT-MLPA probe mix. Annealed oligonucleotides 
were ligated by adding Ligase-65 (MRC-Holland) and 
incubated at 54ºC for 15 min. Ligation products were 
amplified by PCR (35 cycles, 30 s at 95ºC; 30 s at 60ºC, 
and 1 min at 72ºC) with one unlabeled and one FAM-
labeled primer. The final PCR fragments amplified were 
separated by capillary electrophoresis on a 96-capillary 
ABI-Prism® 3730XL Genetic Analyzer (Applied 
Biosystems/Hitachi, Carlsbad, CA, USA). Peak area and 
height were measured using GeneMapperTM v3.0 analysis 
software (Applied Biosystems). Ratios of individual peaks 
relative to the sum of all peaks were calculated, resulting 
in the relative abundance of mRNAs of the genes of 
interest. 
Western blot
Whole cell protein extracts were obtained by 
lysing 2–5 × 106 cells with Laemmli sample buffer. 
Protein concentration was measured with the Micro 
BCATM Protein Assay Reagent kit (Thermo Scientific 
Pierce, Rockford, IL, USA). Protein extracts (25 µg) 
were subjected to reducing conditions before being 
subjected to electrophoresis on a polyacrylamide gel and 
then transferred to Immobilon-P membranes (Millipore, 
Billerica, MA, USA). One hour after blocking with 5% 
(w/v) non-fat milk in Tris-buffered saline with 0.1% 
Tween®-20, the membranes were incubated with the 
specific primary antibodies against BCL-2 (clone 124, 
#M0887, Dako, Denmark), BIM (clone C34C5, #2933, 
Cell Signaling, Danvers, MA, USA), cleaved caspase 3 
(#9661, Cell Signaling), ERK2 (clone 1B3B9, #05-
157, Millipore, Temecula, CA, USA), NOXA (clone 
114C307, #ab13654, Abcam, Cambridge, UK), MCL-1 
(clone S-19, #sc-819, Santa Cruz Biotechnology, Dallas, 
TX, USA), PHB1 (clone H-80, #sc-28259, Santa Cruz 
Biotechnology), PHB2 (anti-REA, #07-234, Millipore), 
PARP (#9542, Cell Signaling), PUMA (#4976, Cell 
Signaling), β-Actin (clone AC-15, #A5441, Sigma-
Aldrich) and Tubulin (clone Ab-1, #CP06, Oncogene, 
Darmstadt, Germany). Antibody binding was detected 
using a secondary antibody conjugated to horseradish 
peroxidase and the enhanced chemiluminescence (ECL) 
detection system (GE Healthcare, Amersham Place, 
Buckinghamshire, UK).
Statistical analysis
Results are shown as the mean  ±  standard error 
of the mean (SEM) of values obtained in three or more 
independent experiments as indicated in each figure 
legend. Data were analyzed using SPSS® Statistics v22.0 
software package (IBM®, Armonk, NY, USA). Two-tailed 
paired or unpaired Student’s t test with normal-based 95% 
CI was used to compare the differences between samples, 
as required. Differences were considered statistically 
significant at p values below 0.05 (*p < 0.05; **p < 0.01; 
***p < 0.001).
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